share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024財年二季報
美股SEC公告 ·  2024/08/13 17:32

Moomoo AI 已提取核心訊息

Tenon Medical reported revenue of $0.9 million for Q2 2024, representing a 21% increase from Q2 2023, driven by a 7% rise in surgical procedures using the Catamaran System. Gross profit improved significantly to $0.47 million with a margin of 52%, up from 26% in the prior year period, due to better production overhead absorption and operating leverage.Operating expenses decreased 4% to $4.3 million, reflecting lower research and development costs and reduced sales and marketing expenses, partially offset by higher general and administrative expenses. The company's net loss narrowed to $3.8 million compared to $4.3 million in Q2 2023, demonstrating improved operational efficiency.The company ended the quarter with $2.0 million in cash and raised additional capital through a private placement of Series A Preferred Stock. However, management indicated substantial doubt about the company's ability to continue as a going concern, citing the need to raise additional capital through equity offerings, debt financing or collaborations to fund operations for the next 12 months.
Tenon Medical reported revenue of $0.9 million for Q2 2024, representing a 21% increase from Q2 2023, driven by a 7% rise in surgical procedures using the Catamaran System. Gross profit improved significantly to $0.47 million with a margin of 52%, up from 26% in the prior year period, due to better production overhead absorption and operating leverage.Operating expenses decreased 4% to $4.3 million, reflecting lower research and development costs and reduced sales and marketing expenses, partially offset by higher general and administrative expenses. The company's net loss narrowed to $3.8 million compared to $4.3 million in Q2 2023, demonstrating improved operational efficiency.The company ended the quarter with $2.0 million in cash and raised additional capital through a private placement of Series A Preferred Stock. However, management indicated substantial doubt about the company's ability to continue as a going concern, citing the need to raise additional capital through equity offerings, debt financing or collaborations to fund operations for the next 12 months.
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Tenon Medical
    TNON
    -- 2.800
    Venus Concept
    VERO
    -- 3.6500
    RxSight
    RXST
    -- 26.670
    Outset Medical
    OM
    -- 12.110
    TELA Bio
    TELA
    -- 1.370
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點